An overview of meningococcal disease in India: Knowledge gaps and potential solutions

Vaccine

Volumn 31, Issue 25, 2013, Pages 2731-2737

  John, T Jacob ^a   Gupta, Sunil ^b   Chitkara, A J ^c   Dutta, Ashok Kumar ^d   Borrow, Ray ^e,f  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b NATIONAL INSTITUTE OF COMMUNICABLE DISEASES   (India)

^c Max Hospital   (India)

^d LADY HARDINGE MEDICAL COLLEGE   (India)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Epidemiology; India; Meningococcal disease; Neisseria meningitidis; Vaccines

Indexed keywords

CEFTRIAXONE; CIPROFLOXACIN; MENINGOCOCCUS VACCINE;

ANTIGEN DETECTION; BACTERIAL MENINGITIS; CHEMOPROPHYLAXIS; DISEASE SURVEILLANCE; EPIDEMIC; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; INCIDENCE; INDIA; MENINGOCOCCOSIS; MORBIDITY; MORTALITY; MULTILOCUS SEQUENCE TYPING; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RAPID RESPONSE TEAM; REVIEW; SOLDIER; VACCINATION;

CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; HUMANS; INCIDENCE; INDIA; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP A; QUALITY OF HEALTH CARE; VACCINATION; VACCINES, CONJUGATE;

EID: 84878355566     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.04.003     Document Type: Review

References (52)

1. Control of Communicable Diseases Manual 2004, American Public Health Association, Washington, D.C. W. Perea, Meningitis, D.L. Heymann (Eds.).
2. Granoff D.M., Harrison L.H., Borrow R. Meningococcal vaccines. Vaccines 2008, 399-434. Saunders Elsevier, Philadelphia, PA. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).
3. Harrison L.H., Pelton S.I., Wilder-Smith A., Holst J., Safadi M.A., Vazquez J.A., et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011, 29(18):3363-3371.
4. Sachdeva A., Kukreja S., Jain V., Dutta A.K. Meningococcal disease-outbreak in Delhi. Indian Pediatr 2005, 42(6):547-556.
5. Sinclair D., Preziosi M.P., Jacob T.J., Greenwood B. The epidemiology of meningococcal disease in India. Trop Med Int Health 2010, 15(12):1421-1435.
6. Prakash K., Lakshmy A., Malhotra V.L. Neisseria meningitidis: serotyping and subtyping by whole cell ELISA. Br J Biomed Sci 1993, 50(3):174-177.
7. Manchanda V., Gupta S., Bhalla P. Meningococcal disease: history, epidemiology, pathogenesis, clinical manifestations, diagnosis, antimicrobial susceptibility and prevention. Indian J Med Microbiol 2006, 24(1):7-19.
8. Jhamb U., Chawla V., Khanna S. Clinical profile of group A meningococcal outbreak in Delhi. Indian Pediatr 2009, 46(9):794-796.
9. Negi S., Grover S., Rautela S., Rawat D., Gupta S., Khare S., et al. Direct detection and serogroup characterization of Neisseria meningitidis from outbreak of meningococcal meningitis in Delhi. Iran J Microbiol 2010, 2(2):73-79.
10. Suri M., Kabra M., Singh S., Rattan A., Verma I.C. Group B meningococcal meningitis in India. Scand J Infect Dis 1994, 26(6):771-773.
11. Gupta P., Choudhury P. Meningococcemia update vaccination and chemoprophylaxis. Indian Pediatr 2005, 42(7):641-644.
12. Sinha K. Severe meningitis outbreak in Meghalaya, Tripura areas. Times of India. Available from: [accessed 30.03.12]. http://articles.timesofindia.indiatimes.com/2009-04-04/india/28045630_1_meningitis-outbreak-meningitis-cases-meningococcal-meningitis.
13. Kumar S., Kashyap B., Bhalla P. The rise and fall of epidemic Neisseria meningitidis from a tertiary care hospital in Delhi, January 2005-June 2007. Trop Doct 2008, 38(4):222-224.
14. National Centre for Disease Control. Meningococcal disease: need to remain alert. National Centre for Disease Control. Available from: [accessed 01.04.12]. http://www.ncdc.gov.in/writereaddata/linkimages/OCT-NOV_098132922884.pdf.
15. Saha R., Gadre D., Mathur M. Meningococcaemia: experience at a tertiary care hospital in East Delhi. Indian J Med Microbiol 2006, 24(4):299-300.
16. Duggal S., Duggal N., Charoo H., Mahajan R.K. Recent outbreak of meningococcal meningitis-a microbiological study with brief review of literature. J Commun Dis 2007, 39(4):209-216.
17. Gorthi S.P., Nagpal B.A.K. Meningococcal vaccine: which, when and for whom?. Med J Armed Forces India 2010, 66(1):2-3.
18. Jha D., Ghosh M.K. Epidemiology of meningococcal carrier state amongst recruits of a military training centre. J Commun Dis 1995, 27(4):250-255.
19. Kushwaha A.S., Aggarwal B.S.K., Arora B.M.M. Outbreak of meningococcal infection amongst soliders deployed in operations. Med J Armed Forces India 2010, 66(1):4-8.
20. Nair D., Dawar R., Deb M., Capoor M.R., Singal S., Upadhayay D.J., et al. Outbreak of meningococcal disease in and around New Delhi, India, 2005-2006: a report from a tertiary care hospital. Epidemiol Infect 2009, 137(4):570-576.
21. Majumdar T., Bhattacharya S., Barman D., Begum R. Laboratory confirmed outbreak of meningococcal infections in Tripura. Indian J Med Microbiol 2011, 29(1):74-76.
22. Indian Academy of Pediatrics Committee on Immunization. IAP Committee guidebook on immunization: 2009-2011. Indian academy of pediatrics. Available from: [accessed 01.04.12]. http://www.iapindia.org/files/IAP%20Immunization%20Guide%20Book_2009_2010.pdf.
23. Singh V, Anchala R, Shukla R, Kadam S, Sathyanarayana T, Tetali S, et al. Competency based training for disease outbreak rapid response teams, Andhra Pradesh State, India. Public Health Foundation of India. Available from: [accessed 01.04.12]. http://www.publichealthglobal.org/index.php%3Foption=com_content%26view=category%26layout=blog%26id=49%26limitstart=10.
24. Lapadula G., Vigano F., Fortuna P., Dolara A., Bramati S., Soria A., et al. Imported ciprofloxacin-resistant Neisseria meningitidis. Emerg Infect Dis 2009, 15(11):1852-1854.
25. Singhal S., Purnapatre K.P., Kalia V., Dube S., Nair D., Deb M., et al. Ciprofloxacin-resistant Neisseria meningitidis, Delhi, India. Emerg Infect Dis 2007, 13(10):1614-1616.
26. Association of Physicians of India The Association of Physicians of India evidence-based clinical practice guidelines on adult immunization. J Assoc Phys India 2009, 57:345-356.
27. Lee C.H., Kuo W.C., Beri S., Kapre S., Joshi J.S., Bouveret N., et al. Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa. Vaccine 2009, 27(5):726-732.
28. Das M. India leads meningitis A vaccine development. Lancet Infect Dis 2004, 4(8):478.
29. Kshirsagar N., Mur N., Thatte U., Gogtay N., Viviani S., Preziosi M.P., et al. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007, 25(Suppl 1):A101-A107.
30. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364(24):2293-2304.
31. Djingarey M.H., Barry R., Bonkoungou M., Tiendrebeogo S., Sebgo R., Kandolo D., et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012, 30(Suppl. 2):B40-B45.
32. Novak R.T., Kambou J.L., Diomandé F.V., Tarbangdo T.F., Ouédraogo-Traoré R., Sangaré L., et al. meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data. Lancet Infect Dis 2012, 12(10):757-764.
33. Kristiansen P.A., Diomandé F., Ky Ba A., Sanou I., Ouédraogo A.-S., Ouédraogo R., et al. Impact of serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity. Clin Infect Dis 2013, 56(3):354-363.
34. Greenwood B. Priorities for research on meningococcal disease and the impact of serogroup A vaccination in the African meningitis belt. Vaccine 2013, 31(11):1453-1457.
35. PATH: A Catalyst for Global Health. 100 millionth person receives lifesaving meningitis vaccine. Available from: [accessed 12.03.13]. http://www.path.org/news/pr121203-menafrivac.php.
36. LaForce F.M., Okwo-Bele J.M. Eliminating epidemic Group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood) 2011, 30(6):1049-1157.
37. Srinivisan R. Health care in India-Vision 2020: issues and prospects. SlideShare Inc. Available from: [accessed 01.04.12]. http://www.slideshare.net/anupsoans/health-care-in-india-vision-2020.
38. PriceWaterhouseCoopers. Access to healthcare: challenges and solutions. PriceWaterhouseCoopers. Available from: [accessed 01.04.12]. http://www.cuts-ccier.org/cohed/pdf/Access_to_Healthcare.pdf.
39. Knowledge for Rural Development. Energy solutions. Knowledge for rural development. Available from: [accessed 01.04.12]. http://www.k4rd.org/e-main.htm.
40. Centers for Disease Control Pediatric Bacterial Meningitis surveillance - African region, 2002-2008. MMWR Morb Mortal Wkly Rep 2009, 58(18):493-497.
41. Meningitis Vaccine Project. MenAfriVac™ reaches three new African countries. Meningitis Vaccine Project. Available from: [accessed 01.04.12]. http://www.meningvax.org/.
42. National Centre for Disease Control. Integrated Disease Surveillance Project (IDSP). National Centre for Disease Control. Available from: [accessed 01.04.12]. http://www.ncdc.gov.in/index2.asp%3Fslid=478%26sublinkid=149.
43. National Centre for Disease Control. Contribution of NCDC in Containment of H1N1 Pandemic in India. National Centre for Disease Control. Available from: [accessed 22.05.12]. http://www.ncdc.gov.in/index3.asp%3Fsslid=522%26subsublinkid=305.
44. Miller M.A., Wenger J., Rosenstein N., Perkins B. Evaluation of meningococcal meningitis vaccination strategies for the meningitis belt in Africa. Pediatr Infect Dis J 1999, 18(12):1051-1059.
45. Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326(7385):365-366.
46. Khatami A., Snape M.D., Davis E., Layton H., John T., Yu L.M., et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine 2012, 30(18):2831-2838.
47. Perrett K.P., Winter A.P., Kibwana E., Jin C., John T.M., Yu L.M., et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clin Infect Dis 2010, 50(12):1601-1610.
48. Borrow R., Joseph H., Andrews N., Acuna M., Longworth E., Martin S., et al. Reduced antibody response to revaccination with meningococcal serogroup A polysaccharide vaccine in adults. Vaccine 2000, 19(9-10):1129-1132.
49. MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998, 280(19):1685-1689.
50. de Whalley P.C., Snape M.D., Kelly D.F., Banner C., Lewis S., Diggle L., et al. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. Pediatr Infect Dis J 2011, 30(11):e203-e208.
51. Borrow R., Goldblatt D., Andrews N., Richmond P., Southern J., Miller E. Influence of prior meningococcal C polysaccharide vaccination on the response and generation of memory after meningococcal C conjugate vaccination in young children. J Infect Dis 2001, 184(3):377-380.
52. Southern J., Deane S., Ashton L., Borrow R., Goldblatt D., Andrews N., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clin Diagn Lab Immunol 2004, 11(6):1100-1104.